{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:54:15Z","timestamp":1788526455725,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Worldwide 85% of cervical cancer (CC) related deaths occur in low- and middle-income countries. Sub-Saharan Africa is burdend by an overlapping high incidence of CC as well as HIV infection, a risk factor for HPV associated disease progression. Recent upscaling of CC screening activities increased the number of CC diagnoses in a previous unscreened population. The aim of the 2H study was to follow up on women with CC in the context of available health care services in Tanzania in relation to their HIV infection status.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This longitudinal observational cohort study included women with histological confirmed CC from Mbeya, Tanzania, between 2013\u20132019. All women were referred for CC staging and cancer-directed therapies (CDT), including surgery and\/or radio-chemotherapy, or palliative care. Annual follow-up focused on successful linkage to CDT, interventions and survival. We assessed factors on compliance, used Kaplan\u2013Meier-Survivor functions to evaluate survival time and poisson regression models to calculate incidence rate ratios on mortality (IRR) two years after diagnosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 270 women with CC (123 HIV infected) were included. Staging information, available in 185 cases, showed 84.9% presented with advanced stage disease (FIGO\u2009\u2265\u2009IIB), no difference was seen in respect to HIV status. HIV-infected women were 12\u00a0years younger at the time of cancer diagnosis (median age 44.8 versus 56.4\u00a0years, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Median follow up period was 11.9\u00a0months (range 0.2\u201367.2). Survival information, available in 231 cases, demonstrated for women diagnosed in early-stage disease a median survival time of 38.3\u00a0months, in advanced-stage 16.0\u00a0months and late-stage disease 6.5\u00a0months after diagnosis. Of all women, 42% received CDT or palliative support. HIV co-infection and education were associated with higher health care compliance. CDT was significantly associated with lower 2-year mortality rates (IRR 0.62, <jats:italic>p<\/jats:italic>\u2009=\u20090.004). HIV coinfection did not impact mortality rates after diagnosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>High numbers of advanced and late staged CC were diagnosed, compliance to CDT was low. A beneficial impact of CDT on CC mortality could be demonstrated for local health care services. This study indicates challenges for successful linkage and supports an effective scale up of cancer care and treatment facilities.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-09966-7","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T09:02:56Z","timestamp":1660554176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Long-term follow-up on HIV infected and non-infected women with cervical cancer from Tanzania: staging, access to cancer-directed therapies and associated survival in a real-life remote setting"],"prefix":"10.1186","volume":"22","author":[{"given":"Laura","family":"Glasmeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby Doryn","family":"Mcharo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liset","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Lennemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Danstan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nice","family":"Mwinuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Judick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert","family":"Mbuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"H\u00f6lscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Lell\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Geldmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Kroidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Rwegoshora","family":"France","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,15]]},"reference":[{"issue":"4","key":"9966_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","volume":"3","author":"C Fitzmaurice","year":"2017","unstructured":"Global Burden of Disease Cancer C, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3(4):524\u201348.","journal-title":"JAMA Oncol"},{"key":"9966_CR2","unstructured":"Ferlay J, Ervik M LF, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, et al. Global Cancer Observatory: Cancer Today 2013 [updated December 2020. Available from: https:\/\/gco.iarc.fr\/today."},{"key":"9966_CR3","unstructured":"World Health Organization. Human papillomavirus (HPV) and cervical cancer 2020 [updated 2021. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/human-papillomavirus-(hpv)-and-cervical-cancer."},{"issue":"3","key":"9966_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"9966_CR5","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","volume":"11","author":"S de Sanjose","year":"2010","unstructured":"de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048\u201356.","journal-title":"Lancet Oncol"},{"issue":"2","key":"9966_CR6","first-page":"94","volume":"20","author":"KO Myers","year":"2018","unstructured":"Myers KO, Ahmed NU. The Role of HIV in the Progression through the Stages of the Human Papillomavirus to Cervical Cancer Pathway. AIDS Rev. 2018;20(2):94\u20131043.","journal-title":"AIDS Rev"},{"issue":"16","key":"9966_CR7","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/jnci\/djp205","volume":"101","author":"AK Chaturvedi","year":"2009","unstructured":"Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst. 2009;101(16):1120\u201330.","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"9966_CR8","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1093\/jnci\/92.18.1500","volume":"92","author":"M Frisch","year":"2000","unstructured":"Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92(18):1500\u201310.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"9966_CR9","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/S2214-109X(20)30459-9","volume":"9","author":"D Stelzle","year":"2021","unstructured":"Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah ASV, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health. 2021;9(2):e161\u20139.","journal-title":"Lancet Glob Health"},{"issue":"31","key":"9966_CR10","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1200\/JCO.2016.67.9613","volume":"34","author":"S Dryden-Peterson","year":"2016","unstructured":"Dryden-Peterson S, Bvochora-Nsingo M, Suneja G, Efstathiou JA, Grover S, Chiyapo S, et al. HIV Infection and Survival Among Women With Cervical Cancer. J Clin Oncol. 2016;34(31):3749\u201357.","journal-title":"J Clin Oncol"},{"issue":"18","key":"9966_CR11","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1097\/01.aids.0000433236.55937.cb","volume":"27","author":"AE Coghill","year":"2013","unstructured":"Coghill AE, Newcomb PA, Madeleine MM, Richardson BA, Mutyaba I, Okuku F, et al. Contribution of HIV infection to mortality among cancer patients in Uganda. AIDS (London, England). 2013;27(18):2933\u201342.","journal-title":"AIDS (London, England)"},{"key":"9966_CR12","doi-asserted-by":"publisher","first-page":"100516","DOI":"10.1016\/j.gore.2019.100516","volume":"31","author":"ES Wu","year":"2020","unstructured":"Wu ES, Urban RR, Krantz EM, Mugisha NM, Nakisige C, Schwartz SM, et al. The association between HIV infection and cervical cancer presentation and survival in Uganda. Gynecologic Oncol Rep. 2020;31:100516.","journal-title":"Gynecologic Oncol Rep"},{"issue":"2","key":"9966_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.4314\/thrb.v11i2.45204","volume":"11","author":"D Mosha","year":"2009","unstructured":"Mosha D, Mahande M, Ahaz J, Mosha M, Njau B, Kitali N, et al. Factors associated with management of cervical cancer patients at KCMC Hospital, Tanzania: a retrospective cross-sectional study. Tanzan J Health Res. 2009;11(2):70\u20134.","journal-title":"Tanzan J Health Res"},{"issue":"1","key":"9966_CR14","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/S2352-3018(17)30149-2","volume":"5","author":"H Kelly","year":"2018","unstructured":"Kelly H, Weiss HA, Benavente Y, de Sanjose S, Mayaud P, Art, et al. Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis. Lancet HIV. 2018;5(1):e45\u201358.","journal-title":"Lancet HIV."},{"key":"9966_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/2046-4053-2-35","volume":"2","author":"L Peirson","year":"2013","unstructured":"Peirson L, Fitzpatrick-Lewis D, Ciliska D, Warren R. Screening for cervical cancer: a systematic review and meta-analysis. Syst Rev. 2013;2:35.","journal-title":"Syst Rev"},{"key":"9966_CR16","volume-title":"Tanzania Service Delivery Guidelines for Cervical Cancer Prevention and Control","author":"The United Republic of Tanzania Ministry of Health","year":"2011","unstructured":"The United Republic of Tanzania Ministry of Health. Tanzania Service Delivery Guidelines for Cervical Cancer Prevention and Control. 2011."},{"key":"9966_CR17","volume-title":"One Plan II: The National Road Map Strategic Plan To Improve Reproductive, Maternal, Newborn, Child & Adolescent Health in Tanzania (2016\u20132020)","author":"The United Republic of Tanzania Ministry of Health","year":"2016","unstructured":"The United Republic of Tanzania Ministry of Health. One Plan II: The National Road Map Strategic Plan To Improve Reproductive, Maternal, Newborn, Child & Adolescent Health in Tanzania (2016\u20132020). 2016."},{"key":"9966_CR18","volume-title":"Comprehensive Cervical Cancer Control: A guide to essential practice - 2nd ed","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. Comprehensive Cervical Cancer Control: A guide to essential practice - 2nd ed. 2014."},{"key":"9966_CR19","unstructured":"Vogel UF. Towards universal access to prevention, treatment and care: experiences and challenges from the Mbeya Region in Tanzania\u2014a case study. Geneva: UNAIDS; 2007. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/jc1291_mbeya_en_0.pdf.."},{"key":"9966_CR20","doi-asserted-by":"publisher","first-page":"763717","DOI":"10.3389\/fonc.2021.763717","volume":"11","author":"R McHaro","year":"2021","unstructured":"McHaro R, Lennemann T, France J, Torres L, Gari M, Mbuya W, et al. HPV Type Distribution in HIV Positive and Negative Women With or Without Cervical Dysplasia or Cancer in East Africa. Front Oncol. 2021;11:763717.","journal-title":"Front Oncol"},{"key":"9966_CR21","doi-asserted-by":"crossref","unstructured":"Solomon D, Davey D, Kurman R, Moriarty A, O\u2019Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287(16):2114\u20139.","DOI":"10.1001\/jama.287.16.2114"},{"issue":"2","key":"9966_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","volume":"105","author":"S Pecorelli","year":"2009","unstructured":"Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105(2):103\u20134.","journal-title":"Int J Gynaecol Obstet"},{"issue":"2","key":"9966_CR23","first-page":"265","volume":"44","author":"MS Piver","year":"1974","unstructured":"Piver MS, Rutledge F, Smith JP. Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol. 1974;44(2):265\u201372.","journal-title":"Obstet Gynecol"},{"issue":"11","key":"9966_CR24","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1002\/ijc.33120","volume":"147","author":"M Sengayi-Muchengeti","year":"2020","unstructured":"Sengayi-Muchengeti M, Joko-Fru WY, Miranda-Filho A, Egue M, Akele-Akpo MT, N\u2019da G, et al. Cervical cancer survival in sub-Saharan Africa by age, stage at diagnosis and Human Development Index: A population-based registry study. Int J Cancer. 2020;147(11):3037\u201348.","journal-title":"Int J Cancer"},{"issue":"5","key":"9966_CR25","doi-asserted-by":"publisher","first-page":"e807","DOI":"10.1002\/onco.13718","volume":"26","author":"M Griesel","year":"2021","unstructured":"Griesel M, Seraphin TP, Mezger NCS, Hammerl L, Feuchtner J, Joko-Fru WY, et al. Cervical Cancer in Sub-Saharan Africa: A Multinational Population-Based Cohort Study of Care and Guideline Adherence. Oncologist. 2021;26(5):e807\u201316.","journal-title":"Oncologist"},{"issue":"1","key":"9966_CR26","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1186\/s12885-020-07439-3","volume":"20","author":"MP Gesink","year":"2020","unstructured":"Gesink MP, Chamberlain RM, Mwaiselage J, Kahesa C, Jackson K, Mueller W, et al. Quantifying the under-estimation of cervical Cancer in remote regions of Tanzania. BMC Cancer. 2020;20(1):939.","journal-title":"BMC Cancer"},{"key":"9966_CR27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.gore.2019.05.008","volume":"29","author":"AS Runge","year":"2019","unstructured":"Runge AS, Bernstein ME, Lucas AN, Tewari KS. Cervical cancer in Tanzania: A systematic review of current challenges in six domains. Gynecologic Oncology Reports. 2019;29:40\u20137.","journal-title":"Gynecologic Oncology Reports"},{"issue":"1","key":"9966_CR28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ijrobp.2018.01.067","volume":"101","author":"S Grover","year":"2018","unstructured":"Grover S, Bvochora-Nsingo M, Yeager A, Chiyapo S, Bhatia R, MacDuffie E, et al. Impact of Human Immunodeficiency Virus Infection on Survival and Acute Toxicities From Chemoradiation Therapy for Cervical Cancer Patients in a Limited-Resource Setting. Int J Radiat Oncol Biol Phys. 2018;101(1):201\u201310.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"9966_CR29","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ygyno.2018.08.038","volume":"151","author":"HM Simonds","year":"2018","unstructured":"Simonds HM, Botha MH, Neugut AI, Van Der Merwe FH, Jacobson JS. Five-year overall survival following chemoradiation among HIV-positive and HIV-negative patients with locally advanced cervical carcinoma in a South African cohort. Gynecol Oncol. 2018;151(2):215\u201320.","journal-title":"Gynecol Oncol"},{"issue":"10","key":"9966_CR30","doi-asserted-by":"publisher","first-page":"e0240154","DOI":"10.1371\/journal.pone.0240154","volume":"15","author":"W Mbuya","year":"2020","unstructured":"Mbuya W, McHaro R, Mhizde J, Mnkai J, Mahenge A, Mwakatima M, et al. Depletion and activation of mucosal CD4 T cells in HIV infected women with HPV-associated lesions of the cervix uteri. PLoS ONE. 2020;15(10):e0240154.","journal-title":"PLoS ONE"},{"key":"9966_CR31","volume-title":"Costing the National Response to Cervical Cancer: United Republic of Tanzania, 2020\u20132024","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. Costing the National Response to Cervical Cancer: United Republic of Tanzania, 2020\u20132024. 2020."},{"issue":"14","key":"9966_CR32","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","volume":"383","author":"J Lei","year":"2020","unstructured":"Lei J, Ploner A, Elfstrom KM, Wang J, Roth A, Fang F, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med. 2020;383(14):1340\u20138.","journal-title":"N Engl J Med"},{"key":"9966_CR33","volume-title":"Global strategy to accelerate the elimination of cervical cancer as a public health problem","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2020."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09966-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09966-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09966-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T09:03:11Z","timestamp":1660554191000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09966-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,15]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["9966"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-09966-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,15]]},"assertion":[{"value":"1 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Mbeya Medical Research and Ethics review Committee, the Tanzanian National Health Research Ethics Committee, and the Ethics Committee of the University Munich (LMU). All methods were carried out in accordance with relevenat guidelines and regulations. The study had been fully explained and answers were responded before written informed consent was obtained from the participant. In case of illiterate study participant a thumb print was provided by the participant and the form had to be signed by an impartial witness. This informed consent method, including for illiterate study participants, was approved by all involved ethic comittees: the local Mbeya Medical Research and Ethics review Committee, the Tanzanian National Health Research Ethics Commitee and the ethics committee of the Ludwig-Maximilian-University in Munich, Germany.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"892"}}